

Randomised trial of Methotrexate in CIDP (RMC trial)

This is a new research trial taking place in Great Britain and Europe. It aims to see if methotrexate is useful for treating CIDP. It is a drug which suppresses the immune system. It helps and is reasonably safe in rheumatoid arthritis and some other diseases. Preliminary reports suggest that it might help in CIDP. To test this properly, some people in the trial will take methotrexate and some will take a placebo. A placebo is a dummy pill which looks like the real thing but is not. It contains no active ingredient.

The trial will test if people taking methotrexate can manage with a lower dose of intravenous immunoglobulin (IVIg) or steroids than those not taking methotrexate. It will also measure whether methotrexate improves CIDP symptoms. The trial is likely to recruit people from February until December 2006. It will take place in several centres all over England, in Cardiff and in Glasgow.

To take part you need to have CIDP **and be on steroids or IVIg or both for at least 3 months.**

If you are interested in taking part and would like more information please contact:

Eileen Evers
evers@cidp.fsnet.co.uk

or

Deb Anderson
eightplusfive@hotmail.com

Contacting us does not place you under any obligation to take part.

Professor Richard Hughes Chief Investigator